Gilead Sciences Inc. and Merck & Co. said an experimental long acting pill combining two HIV medicines had met its primary ...

Merck & Co. says it will settle a spate of lawsuits that blame the drugmaker’s blockbuster Gardasil cancer vaccine for ...

Merck (NYSE:MRK) has agreed to a settlement worth more than $50m to resolve over 200 lawsuits related to its Gardasil HPV ...

Merck Appoints New Heads of Discovery Solutions and Strategy & Business Development for Life Science Business Sector ...

Rejuvenate Bio, a biotechnology company developing gene therapies for age-related and chronic diseases, today announced the ...

Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.

A cross-border investigation by DW and ICIJ reveals how pricing and patents helped turn a life-saving medicine into one of ...

Chicago, IL – June 8, 2026 – Today, Zacks Investment Ideas feature highlights Eli Lilly LLY and Merck MRK. There's an old ...

More biopharma layoffs are hitting New Jersey, this time from Merck & Co.in the latest phase of headcount reductions ...

Merck has rebounded 55% in the past year, driven by optimism around its post-Keytruda strategy despite the looming patent ...

Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products.  The pharmaceutical giant also narrowed its 2026 sales ...

Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside Keytruda saw their risk of disease ...